Semaglutide is the active ingredient in medications you may know as Wegovy or Ozempic. It belongs to a class called GLP-1 receptor agonists, which work on the hormone signals that govern appetite and how full you feel after eating. For many patients that changes the experience of a meal rather than requiring constant willpower. It is not right for everyone, and eligibility here is determined by a physician after an evaluation and lab work, never by a form or a quick phone call.
There is a practical reason patients from Chamblee handle this well. The drive is short and predictable, either southwest on Peachtree Road and over on Johnson Ferry Road to Roswell Road, or west on I-285 and down from the north. Our office sits just inside the Perimeter near Chastain Park. That matters because GLP-1 treatment is not a single visit. Doses start low and are adjusted gradually, side effects like nausea need to be discussed honestly, and someone should be watching your labs the whole way.
We also spend real time on what happens alongside the medication. Protein intake, some form of resistance work so that muscle is protected, and a plan for what the food part of your life looks like long term. Chamblee residents rarely want to give up the Buford Highway table, and they should not have to. The goal is a way of eating you can hold onto, with your physician deciding how long medication stays part of the picture.
About GLP-1 Semaglutide Weight Loss
Semaglutide belongs to a class of medications called GLP-1 receptor agonists. GLP-1 is a hormone the small intestine releases after eating, and it is part of how the body signals fullness to the brain. Semaglutide imitates that signal: it slows how quickly the stomach empties, blunts the hunger and food-preoccupation that make calorie restriction so hard to sustain, and helps the pancreas release insulin in response to meals. The practical effect for most patients is not willpower arriving out of nowhere. It is that the constant background pull toward food quiets down enough for real dietary changes to hold.
Under the brand name Wegovy, semaglutide is FDA-approved for chronic weight management in adults with a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related condition such as type 2 diabetes, high blood pressure, high cholesterol, obstructive sleep apnea, or cardiovascular disease. It is approved for use alongside a reduced-calorie diet and increased physical activity, not as a stand-alone substitute for them. Ozempic is the same molecule approved for type 2 diabetes. In December 2025 the FDA also approved a once-daily oral form of semaglutide for weight management, the first GLP-1 pill cleared for that use, which gives physicians an option for patients who are not candidates for or not comfortable with a weekly injection. Tirzepatide, marketed as Mounjaro and Zepbound, works on both the GLP-1 and GIP receptors and is a separate medication your physician may discuss with you.
At Atlanta Medical Institute, semaglutide is prescribed as one part of physician-supervised obesity treatment rather than as a product you simply order. Our physicians have treated weight as a chronic medical condition since 2010, and that framing shapes how the medication is used: an evaluation and appropriate lab work before the first dose, a starting dose chosen for tolerability rather than speed, scheduled follow-up to adjust the plan, and attention to nutrition, protein intake, and muscle preservation throughout. Whether semaglutide is appropriate for you, and which formulation makes sense, is a medical decision your physician makes with you after reviewing your history.
How Semaglutide Works
Appetite is regulated by hormones, not by character. People carrying excess weight often have blunted satiety signaling, which is one reason conventional dieting fails so reliably over the long run: the body defends its higher weight with hunger and a slowed metabolic rate. Semaglutide acts on several of those pathways at once.
Because the medication changes how full you feel and how quickly food leaves the stomach, portion sizes usually fall on their own rather than through deliberate restriction. Most patients notice this within the first several weeks, though the degree varies a great deal from person to person and by dose.
- Acts on GLP-1 receptors in the brain regions that govern appetite and satiety
- Slows gastric emptying, so meals stay satisfying longer
- Supports glucose-dependent insulin release, which helps blood sugar control in patients with type 2 diabetes
- Reduces food-seeking behavior and, for many patients, the intrusive food thoughts often described as food noise
- Is taken as a once-weekly injection, or as a once-daily tablet in the oral form approved for weight management
Who Is a Candidate
Candidacy is determined by a medical evaluation, not by a questionnaire. Our physicians review your weight history, prior attempts at weight loss, current medications, and any conditions that make weight loss medically important, such as prediabetes, type 2 diabetes, hypertension, elevated lipids, fatty liver disease, sleep apnea, PCOS, or joint disease. Baseline labs are typically part of that workup, and thyroid, kidney, and metabolic status are reviewed before a prescription is written.
Some patients should not take semaglutide at all, and others need closer supervision or a different medication entirely. The list below covers the most common reasons a physician will steer away from it. It is not complete, which is exactly why the evaluation matters.
- Personal or family history of medullary thyroid carcinoma, or Multiple Endocrine Neoplasia syndrome type 2, which are contraindications
- Prior serious hypersensitivity reaction to semaglutide or any component of the product
- Pregnancy, planning pregnancy, or breastfeeding
- History of pancreatitis, gallbladder disease, gastroparesis, or significant gastrointestinal disease
- Type 1 diabetes, or type 2 diabetes treated with insulin or a sulfonylurea, where doses may need adjusting to avoid low blood sugar
- Active diabetic retinopathy, which warrants ophthalmologic follow-up during rapid glucose improvement
- A history of an eating disorder, or a BMI below the approved thresholds
What Treatment Involves
Semaglutide is started low and increased slowly. The weekly injectable form typically begins at 0.25 mg, with increases about every four weeks as tolerated, working toward a maintenance dose that may go up to 2.4 mg. The oral form has its own titration schedule and specific instructions about taking it on an empty stomach. These schedules are a framework, not a race. If side effects appear at a given step, your physician may hold you at that dose longer or move back down, and plenty of patients do well at a dose below the maximum.
Follow-up visits are where the actual work happens. Weight, blood pressure, and relevant labs are tracked, side effects are addressed, and the dose is adjusted based on how you are responding rather than on a fixed calendar. Our physicians also use these visits to keep nutrition on track, because appetite suppression without adequate protein and resistance training tends to cost lean muscle along with fat.
Semaglutide is not a short course of treatment in the way an antibiotic is. Obesity behaves like a chronic condition, and the medication manages it while it is being taken. In the STEP 1 trial extension, participants regained about two-thirds of the weight they had lost within a year of stopping. That is not a reason to avoid treatment; it is a reason to plan for the long term from the beginning, and to discuss maintenance strategy with your physician well before any decision to taper or stop.
Side Effects, Monitoring, and Safety
The most common side effects are gastrointestinal: nausea, vomiting, diarrhea, constipation, abdominal discomfort, and reflux. They cluster in the first few weeks after starting and after each dose increase, and they usually ease as the body adapts. Smaller meals, slower eating, lower fat content, and adequate fluids all help. Persistent vomiting or diarrhea can cause dehydration and affect kidney function, so it should be reported rather than endured.
Less common but more serious risks carry specific warnings on the FDA label. Acute pancreatitis has been reported with GLP-1 medications; severe, persistent abdominal pain, with or without vomiting, warrants immediate medical attention and discontinuation. Gallstones and gallbladder inflammation occur more often during rapid weight loss. Semaglutide caused thyroid C-cell tumors in rodents at clinically relevant exposures, and whether it does so in humans is unknown, which is the basis for the boxed warning and the contraindications noted above. Patients on insulin or sulfonylureas can experience low blood sugar and may need those doses reduced.
Two practical points get overlooked often enough to be worth stating plainly. First, because semaglutide slows gastric emptying, tell any surgeon, anesthesiologist, or proceduralist that you are taking it, since food retained in the stomach raises aspiration risk under sedation or general anesthesia. Second, tell every clinician treating you, including your primary care physician, what dose you are on. Our physicians coordinate with outside providers when that is useful, and we would rather have the full picture than manage around a gap in it.
- Report severe or persistent abdominal pain, ongoing vomiting, or signs of dehydration right away
- Tell your care team before any surgery, endoscopy, or procedure requiring sedation
- Emphasize protein intake and resistance training to help preserve lean muscle during weight loss
- Expect periodic labs and in-person follow-up rather than automatic refills
- Discuss any new or changing medications, particularly diabetes medications, with your prescribing physician
Getting Here from Chamblee
Most patients from Chamblee head southwest on Peachtree Road through Brookhaven and cut over on Windsor Parkway or Johnson Ferry Road to Roswell Road, while others take I-285 west and come down Roswell Road from the north; either way the office sits just inside the Perimeter near Chastain Park.
5009 Roswell Road NE, Suite 201
Atlanta, GA 30342
We see patients from across Chamblee and nearby areas including Huntley Hills, Keswick Village, Sexton Woods, Historic Downtown Chamblee, Beverly Hills/Beverly Woods.
Semaglutide (GLP-1) Weight Loss in Chamblee — Frequently Asked Questions
Do I have to have diabetes to be considered for semaglutide?
No. Semaglutide is prescribed for weight management as well as for type 2 diabetes, and the two uses have different brand names and dosing. Whether it is appropriate for you depends on your medical evaluation, your health history and your lab results.
Can patients from Chamblee do any of this by phone?
Some follow-up conversations can be handled remotely, but the initial evaluation and lab work are done in person at our Atlanta office on Roswell Road. Call (404) 341-4819 to ask what your specific situation would require.
How much weight will I lose on semaglutide?
We will not give you a number. Results vary widely between patients, and some people do not respond well to GLP-1 medication at all. Your physician will track your progress and adjust the plan based on what actually happens.
Is semaglutide the same thing as Ozempic and Wegovy?
Semaglutide is the active medication; Ozempic and Wegovy are brand names for it. Ozempic is FDA-approved to treat type 2 diabetes, and Wegovy is FDA-approved for chronic weight management in adults who meet the BMI criteria, as well as for reducing cardiovascular risk in certain patients. A once-daily oral form of semaglutide was also approved for weight management in December 2025. Your physician will determine which product and which form fits your diagnosis and history.
How quickly will I notice a difference?
Many patients notice reduced appetite within the first few weeks, often before the scale moves much, because the starting dose is deliberately low and increases gradually. Meaningful weight change typically unfolds over months rather than weeks, and it varies considerably between individuals. We do not promise a specific number of pounds, and you should be cautious of anyone who does.
What is the difference between compounded semaglutide and the FDA-approved version?
FDA-approved semaglutide products are manufactured and tested under FDA oversight with an approved label. Compounded versions are prepared by compounding pharmacies and are not FDA-approved, reviewed for safety and effectiveness, or subject to the same manufacturing standards. Wide-scale compounding of semaglutide copies was permitted during the national shortage, but the FDA removed semaglutide from its shortage list in February 2025 and the compounding pathways narrowed considerably through 2025 and 2026. The FDA has also warned about unapproved and counterfeit GLP-1 products sold online and through unlicensed sellers. Ask any provider directly what they are prescribing and where it comes from, and discuss the differences with your physician before starting.
Do I still have to change how I eat and exercise?
Yes. Semaglutide is approved for use along with a reduced-calorie diet and increased physical activity, not in place of them. The medication makes those changes far more achievable by quieting hunger, but nutrition still determines the quality of the weight you lose. Protein intake and resistance training in particular help protect lean muscle, which is why our physicians build them into the plan rather than treating them as optional extras.
What happens if I stop taking it?
Appetite generally returns, and weight regain is common. In the STEP 1 trial extension, participants regained roughly two-thirds of the weight they had lost within a year of stopping. Obesity is a chronic condition, and semaglutide manages it while it is being taken. If you and your physician decide to stop or taper, that decision should come with a maintenance plan rather than an abrupt end to care.
How is semaglutide different from tirzepatide?
Tirzepatide, sold as Mounjaro and Zepbound, acts on both the GIP and GLP-1 receptors, while semaglutide acts on the GLP-1 receptor alone. Both are given as weekly injections and both require titration. In studies and in practice, some patients respond better to one than the other, and tolerability, medical history, coverage, and availability all factor into the choice. Anyone switching between them starts the new medication at its lowest dose regardless of the dose they were on before. Your physician will discuss which is the better fit for you.
Want the full clinical detail? Read about our Semaglutide Program program.